Novartis’s heart failure drug Entresto failed a test in a new use, the Swiss drug producer said on Monday, calling into question billions of dollars in potential income and taking the shine off one of the firm’s biggest growth prospects.
The medicine, already authorised for reduced fraction heart failure, “narrowly missed” its objectives when examined in patients with preserved ejection fraction type of heart condition which affects 13 million globally, roughly half of all heart failure sufferers, the corporate stated in a statement.
Twice-a-day Entresto has the potential for over $3 billion annual sales for the current evidence in patients whose heart muscles do not contract successfully, Novartis has said.
With a possible new sign in heart failure sufferers in whom the heart muscle contracts usually; however, the ventricles do not relax as they need to, the Basel-based drug producer witnessed total annual sales rising to as much as $5 billion. The failure in this trial in 4,822 patients puts the grown sales at risk.
The Paragon HF trial compared Entresto versus the older drug valsartan, which Novartis sells under the company name Diovan.
Entresto began out slow following its 2015 approval; however, has just lately picked up momentum, with income rising about 80% in H1 of 2019 to $778 million globally as doctors moved treatment from older medicines.
Novartis said it would show the results of the trial at the European Society of Cardiology in September, and talk about next steps with scientific experts and regulators.
The corporate’s shares dropped 1.4% to 91.20 Swiss francs ($91.90) in early trading in Zurich after the news.